Skip to main content
Erschienen in: Medizinische Klinik - Intensivmedizin und Notfallmedizin 2/2018

07.02.2018 | Harnwegsinfektionen | CME

Urosepsis

verfasst von: Prof. Dr. med. Mathias W. Pletz, PD Dr.med. Sebastian Weis, PD Dr. med. Christina Forstner, Prof. Dr. med. Florian Wagenlehner

Erschienen in: Medizinische Klinik - Intensivmedizin und Notfallmedizin | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Urosepsis ist als schweres Krankheitsbild durch Organversagen aufgrund einer Harnwegsinfektion definiert. Eine empirische Antibiotikatherapie sollte innerhalb der ersten Stunde nach Diagnose erfolgen. Des Weiteren sollten Urin- und Blutkulturen vor Antibiotikatherapie angelegt werden. Eine weiterführende Diagnostik sollte frühzeitig erfolgen, um ggf. eine (innerhalb von 6 h) interventionelle Fokuskontrolle bei Harnwegsobstruktion und Abszessen zu ermöglichen. Gramnegative Erreger werden am häufigsten isoliert. ESBL(„extended-spectrum beta-lactamase“)-Bildner als Erreger der Urosepsis nehmen zu. Carbapenemase-bildende Enterobacteriaceae sind dagegen derzeit noch selten. Die empirische Therapie besteht aus einem Breitspektrumbetalaktamantibiotikum. Während Piperacillin/Tazobactam, Carbapeneme und die neuen Cephalosporin/BLI(Betalaktamaseinhibitoren)-Kombinationen bei ausreichender Empfindlichkeit als Monotherapie gegeben werden können, sollten Cephalosporine mit Aminoglykosiden (bevorzugt) oder Fluorochinolonen kombiniert werden. Wird eine Kombinationstherapie gegeben, sollte nach 48–72 h auf eine Monotherapie deeskaliert werden.
Literatur
1.
Zurück zum Zitat Fleischmann C, Scherag A, Adhikari NK et al (2016) Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193:259–272CrossRefPubMed Fleischmann C, Scherag A, Adhikari NK et al (2016) Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193:259–272CrossRefPubMed
2.
3.
Zurück zum Zitat Engel C, Brunkhorst FM, Bone HG et al (2007) Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33:606–618CrossRefPubMed Engel C, Brunkhorst FM, Bone HG et al (2007) Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33:606–618CrossRefPubMed
4.
Zurück zum Zitat Qiang XH, Yu TO, Li YN et al (2016) Prognosis risk of urosepsis in critical care medicine: a prospective observational study. Biomed Res Int 2016:9028924CrossRefPubMedPubMedCentral Qiang XH, Yu TO, Li YN et al (2016) Prognosis risk of urosepsis in critical care medicine: a prospective observational study. Biomed Res Int 2016:9028924CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:801–810CrossRefPubMedPubMedCentral Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:801–810CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bodmann KF, Grabein B, EDP-E-GFC EV (2017) S2k Leitline: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen be Erwachsenen-Update 2017. AWMF Leitlinie AWMF RegNo 082-006. Bodmann KF, Grabein B, EDP-E-GFC EV (2017) S2k Leitline: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen be Erwachsenen-Update 2017. AWMF Leitlinie AWMF RegNo 082-006.
7.
Zurück zum Zitat Tandogdu Z, Bartoletti R, Cai T et al (2016) Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013. World J Urol 34:1193–1200CrossRefPubMed Tandogdu Z, Bartoletti R, Cai T et al (2016) Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013. World J Urol 34:1193–1200CrossRefPubMed
8.
Zurück zum Zitat Demuth PJ, Gerding DN, Crossley K (1979) Staphylococcus aureus bacteriuria. Arch Intern Med 139:78–80CrossRefPubMed Demuth PJ, Gerding DN, Crossley K (1979) Staphylococcus aureus bacteriuria. Arch Intern Med 139:78–80CrossRefPubMed
9.
10.
Zurück zum Zitat Chihara S, Popovich KJ, Weinstein RA et al (2010) Staphylococcus aureus bacteriuria as a prognosticator for outcome of staphylococcus aureus bacteremia: a case-control study. BMC Infect Dis 10:225CrossRefPubMedPubMedCentral Chihara S, Popovich KJ, Weinstein RA et al (2010) Staphylococcus aureus bacteriuria as a prognosticator for outcome of staphylococcus aureus bacteremia: a case-control study. BMC Infect Dis 10:225CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285–292CrossRefPubMed Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285–292CrossRefPubMed
12.
Zurück zum Zitat Nissen JL, Skov R, Knudsen JD et al (2013) Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis. J Antimicrob Chemother 68:1894–1900CrossRefPubMed Nissen JL, Skov R, Knudsen JD et al (2013) Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis. J Antimicrob Chemother 68:1894–1900CrossRefPubMed
14.
Zurück zum Zitat Kaukonen KM, Bailey M, Pilcher D et al (2015) Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 372:1629–1638CrossRefPubMed Kaukonen KM, Bailey M, Pilcher D et al (2015) Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 372:1629–1638CrossRefPubMed
15.
Zurück zum Zitat Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:762–774CrossRefPubMedPubMedCentral Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:762–774CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Churpek MM, Snyder A, Han X et al (2017) Quick sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores for detecting clinical deterioration in infected patients outside the intensive care unit. Am J Respir Crit Care Med 195:906–911CrossRefPubMed Churpek MM, Snyder A, Han X et al (2017) Quick sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores for detecting clinical deterioration in infected patients outside the intensive care unit. Am J Respir Crit Care Med 195:906–911CrossRefPubMed
17.
Zurück zum Zitat Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377CrossRefPubMed Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377CrossRefPubMed
19.
Zurück zum Zitat Van Nieuwkoop C, Bonten TN, Van’t Wout JW et al (2010) Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 14:R206CrossRefPubMedPubMedCentral Van Nieuwkoop C, Bonten TN, Van’t Wout JW et al (2010) Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 14:R206CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat High KP, Bradley SF, Gravenstein S et al (2009) Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. J Am Geriatr Soc 57:375–394CrossRefPubMed High KP, Bradley SF, Gravenstein S et al (2009) Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. J Am Geriatr Soc 57:375–394CrossRefPubMed
22.
Zurück zum Zitat Rodriguez-Bano J, Navarro MD, Retamar P et al (2012) beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:167–174CrossRefPubMed Rodriguez-Bano J, Navarro MD, Retamar P et al (2012) beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:167–174CrossRefPubMed
23.
Zurück zum Zitat Leclercq R, Canton R, Brown DF et al (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141–160CrossRefPubMed Leclercq R, Canton R, Brown DF et al (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141–160CrossRefPubMed
24.
Zurück zum Zitat Tamma PD, Han JH, Rock C et al (2015) Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis 60:1319–1325PubMedPubMedCentral Tamma PD, Han JH, Rock C et al (2015) Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis 60:1319–1325PubMedPubMedCentral
25.
Zurück zum Zitat Carmeli Y, Armstrong J, Laud PJ et al (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661–673CrossRefPubMed Carmeli Y, Armstrong J, Laud PJ et al (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661–673CrossRefPubMed
26.
Zurück zum Zitat Wagenlehner FM, Sobel JD, Newell P et al (2016) Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63:754–762CrossRefPubMedPubMedCentral Wagenlehner FM, Sobel JD, Newell P et al (2016) Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63:754–762CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Wagenlehner FM, Umeh O, Steenbergen J et al (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949–1956CrossRefPubMed Wagenlehner FM, Umeh O, Steenbergen J et al (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949–1956CrossRefPubMed
28.
Zurück zum Zitat Staley C, Vaughn BP, Graiziger CT et al (2017) Gut-sparing treatment of urinary tract infection in patients at high risk of clostridium difficile infection. J Antimicrob Chemother 72:522–528CrossRefPubMed Staley C, Vaughn BP, Graiziger CT et al (2017) Gut-sparing treatment of urinary tract infection in patients at high risk of clostridium difficile infection. J Antimicrob Chemother 72:522–528CrossRefPubMed
29.
Zurück zum Zitat Cek M, Tandogdu Z, Wagenlehner F et al (2014) Healthcare-associated urinary tract infections in hospitalized urological patients – a global perspective: results from the GPIU studies 2003–2010. World J Urol 32:1587–1594CrossRefPubMed Cek M, Tandogdu Z, Wagenlehner F et al (2014) Healthcare-associated urinary tract infections in hospitalized urological patients – a global perspective: results from the GPIU studies 2003–2010. World J Urol 32:1587–1594CrossRefPubMed
31.
Zurück zum Zitat Hofmann W (1990) Urosepsis and uroseptic shock. Z Urol Nephrol 83:317–324PubMed Hofmann W (1990) Urosepsis and uroseptic shock. Z Urol Nephrol 83:317–324PubMed
32.
Zurück zum Zitat Dreger NM, Degener S, Ahmad-Nejad P et al (2015) Urosepsis – etiology, diagnosis, and treatment. Dtsch Arztebl Int 112:837–847 (quiz 848)PubMedPubMedCentral Dreger NM, Degener S, Ahmad-Nejad P et al (2015) Urosepsis – etiology, diagnosis, and treatment. Dtsch Arztebl Int 112:837–847 (quiz 848)PubMedPubMedCentral
33.
Zurück zum Zitat Wagenlehner FM, Lichtenstern C, Weigand MA et al (2010) Urosepsis and treatment. Urologe A 49:618–622CrossRefPubMed Wagenlehner FM, Lichtenstern C, Weigand MA et al (2010) Urosepsis and treatment. Urologe A 49:618–622CrossRefPubMed
34.
Zurück zum Zitat Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377CrossRefPubMed Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377CrossRefPubMed
35.
Zurück zum Zitat Nguyen HB, Jaehne AK, Jayaprakash N et al (2016) Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE. Crit Care 20:160CrossRefPubMedPubMedCentral Nguyen HB, Jaehne AK, Jayaprakash N et al (2016) Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE. Crit Care 20:160CrossRefPubMedPubMedCentral
Metadaten
Titel
Urosepsis
verfasst von
Prof. Dr. med. Mathias W. Pletz
PD Dr.med. Sebastian Weis
PD Dr. med. Christina Forstner
Prof. Dr. med. Florian Wagenlehner
Publikationsdatum
07.02.2018
Verlag
Springer Medizin
Erschienen in
Medizinische Klinik - Intensivmedizin und Notfallmedizin / Ausgabe 2/2018
Print ISSN: 2193-6218
Elektronische ISSN: 2193-6226
DOI
https://doi.org/10.1007/s00063-018-0406-1

Weitere Artikel der Ausgabe 2/2018

Medizinische Klinik - Intensivmedizin und Notfallmedizin 2/2018 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.